Valneva (NASDAQ:VALN) Trading 2.3% Higher - Time to Buy?

Valneva SE (NASDAQ:VALN - Get Free Report) shares were up 2.3% on Friday . The company traded as high as $7.45 and last traded at $7.42. Approximately 6,542 shares were traded during trading, a decline of 75% from the average daily volume of 25,882 shares. The stock had previously closed at $7.25.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Guggenheim dropped their price target on shares of Valneva from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Valneva in a report on Friday.

Valneva Price Performance

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business's 50-day simple moving average is $6.45 and its two-hundred day simple moving average is $5.59. The firm has a market cap of $574.52 million, a price-to-earnings ratio of -54.38 and a beta of 1.93.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The firm had revenue of $56.48 million for the quarter, compared to analyst estimates of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. As a group, research analysts expect that Valneva SE will post 0.13 EPS for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN increased its holdings in shares of Valneva SE (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 246,766 shares of the company's stock after purchasing an additional 30,859 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 at the end of the most recent quarter. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.